We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest close session, Gilead Sciences (GILD - Free Report) was up +1.19% at $113.59. This change outpaced the S&P 500's 0.48% gain on the day. At the same time, the Dow added 0.27%, and the tech-heavy Nasdaq gained 0.94%.
The HIV and hepatitis C drugmaker's shares have seen a decrease of 5.45% over the last month, not keeping up with the Medical sector's gain of 1.09% and the S&P 500's gain of 2.46%.
Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 6.44% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 billion, showing a 1.63% drop compared to the year-ago quarter.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $8.1 per share and revenue of $28.75 billion. These results would represent year-over-year changes of +75.32% and 0%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% lower. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 13.86. For comparison, its industry has an average Forward P/E of 20.03, which means Gilead Sciences is trading at a discount to the group.
We can also see that GILD currently has a PEG ratio of 0.76. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.64.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
In the latest close session, Gilead Sciences (GILD - Free Report) was up +1.19% at $113.59. This change outpaced the S&P 500's 0.48% gain on the day. At the same time, the Dow added 0.27%, and the tech-heavy Nasdaq gained 0.94%.
The HIV and hepatitis C drugmaker's shares have seen a decrease of 5.45% over the last month, not keeping up with the Medical sector's gain of 1.09% and the S&P 500's gain of 2.46%.
Investors will be eagerly watching for the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $2.15, reflecting a 6.44% increase from the same quarter last year. Simultaneously, our latest consensus estimate expects the revenue to be $7.42 billion, showing a 1.63% drop compared to the year-ago quarter.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $8.1 per share and revenue of $28.75 billion. These results would represent year-over-year changes of +75.32% and 0%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Gilead Sciences. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% lower. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now.
Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 13.86. For comparison, its industry has an average Forward P/E of 20.03, which means Gilead Sciences is trading at a discount to the group.
We can also see that GILD currently has a PEG ratio of 0.76. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.64.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.